Grants for Small businesses - Science and Technology

This challenge invites engineers and materials innovators worldwide to create a cost-effective, corrosion-resistant lining for flow meters used in harsh industrial environments, with the potential for significant monetary awards and collaboration opportunities with a leading automation company.

This funding opportunity invites a wide range of organizations, including academic institutions and businesses, to propose innovative research and technology projects that enhance naval aviation capabilities for the U.S. Navy.

This grant provides access to advanced genetic and genomic analysis services for research projects focused on understanding genetic factors in human health and disease, particularly those linked to existing NIH research grants.

This grant provides funding for innovative research projects aimed at improving the understanding and treatment of eye injuries and visual dysfunction related to military service.

This funding opportunity supports community-based healthcare organizations in implementing educational initiatives and system-level changes to improve care for patients with relapsed or refractory multiple myeloma, particularly through the use of bispecific antibody therapies.

This funding opportunity supports nonprofit organizations in New Jersey that are dedicated to improving the social, economic, and educational outcomes of Hispanic communities through various initiatives.

This grant provides funding and support to early-stage U.S. startups developing innovative technologies that can meet critical needs of the Department of Defense.

This program provides funding for researchers and innovators to develop advanced technologies for rapidly identifying and sequencing complex protein-based biothreats, enhancing national security and defense capabilities.

This funding opportunity supports various organizations in recruiting and managing participants with kidney diseases for a national study aimed at improving understanding and treatment of these conditions.

This grant option, part of the Minnesota Spinal Cord Injury and Traumatic Brain Injury Research Grant Program, aims to support early-stage research into innovative treatments and rehabilitative techniques for spinal cord and traumatic brain injuries. The Tier 1 Pilot Project Grant does not require preliminary data but encourages it, reflecting early investment as researchers prepare to seek larger grants. The funding amount can reach up to $125,000 for a project duration of two years with an additional one-year no-cost extension.

This funding opportunity provides financial support to U.S.-based small businesses that have previously received Phase I awards to further develop and commercialize innovative research in agriculture, food systems, and environmental sustainability.

This grant provides funding for U.S.-based researchers and organizations to conduct innovative studies in microgravity that explore transport phenomena, with the goal of developing solutions that benefit life on Earth.

This grant provides funding for innovative research on brain and nervous system disorders, encouraging collaboration between U.S. and low- and middle-income country researchers to improve global health outcomes.

This grant provides funding to early-stage companies in the U.S. and Canada that are developing innovative software and AI solutions aimed at combating climate change and promoting sustainability.

This grant provides financial assistance to businesses in Takoma Park for enhancing their storefronts, promoting a vibrant commercial environment.

This funding opportunity provides financial support for research projects that explore the connections between drug markets, firearm-related violence, and effective law enforcement strategies, targeting a wide range of eligible applicants including governments, educational institutions, and nonprofit organizations.

The CATALYST Grant aims to enhance the capabilities, efficiency, and competitiveness of small and medium-sized manufacturers in South Carolina by promoting the adoption of Advanced Manufacturing Technologies (AMT), Quality Management Systems (QMSs), and Lean Manufacturing tools. Eligible manufacturers must have a NAICS code beginning with 31, 32, or 33, be physically located in South Carolina for at least one year, operate within the Department of Defense supply chain, and employ at least four workers. The grant supports consultative assessments to identify opportunities for AMT deployment and funds pilot projects in areas such as augmented reality training, digital work instructions, and robotics. The grant application opens on October 5, 2023, following an informational webinar, and closes on June 30, 2024, or when all slots are filled. The grant provides funding for projects recommended by AMT assessments, as well as QMS and Lean Manufacturing implementations to help manufacturers eliminate waste and reduce rework, improving their effectiveness as DIB suppliers.

This funding opportunity supports U.S.-based small businesses in developing and manufacturing therapeutic extracellular vesicles for regenerative medicine applications, focusing on tissue and organ repair.

The FY24 DMDRP CTRA mechanism supports advanced translational research that will accelerate the movement of promising ideas in DMD research into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. However, applicants should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between applied and clinical research. As such, applications must include preliminary and/or published data relevant to DMD to support the proposed research project.This mechanism is intended to support established projects that have moved beyond the realm of basic research and proof of concept studies and have the potential to result in a near-term impact in clinical research or the clinic. Research projects investigating therapies that will be efficacious across the life span, including infants, toddlers, and non-ambulatory individuals, are strongly encouraged. Pilot, proof-of-principle clinical trials, and correlative studies to better inform development of drugs, devices, and other interventions are allowed.Early-Career Partnering PI Option: The FY24 DMDRP encourages applications that include meaningful and productive collaborations between investigators. In an effort to promote enhanced research capacity within the DMD field, the FY24 CTRA includes an option for an Early-Career Partnering Principal Investigator (PI). The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Early-Career PI will be identified as the Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.The FY24 DMDRP CTRA offers two funding levels (refer to Section II.D.5 Funding Restrictions). Only one funding level category may be chosen per application, and the choice of application category is at the discretion of the applicant. The following are generalized descriptions of the scope of the research appropriate for each funding level:Funding Level 1: Funding Level 1 is intended to support smaller, less complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $650,000.Funding Level 2: Funding Level 2 is intended to support larger, more complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $1.35M.Additionally, both funding levels will support an Early-Career Partnering PI Option at the same maximum direct costs and periods of performance, respectively.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Both pilot clinical trials and clinical research are permitted under this mechanism.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.All investigators applying to FY24 DMDRP funding opportunities and conducting clinical research are encouraged to consult the Strategies to Promote Diversity in Muscular Dystrophy Research Participation developed by the MDCC.

This funding opportunity provides financial support for the design and operation of a facility that extracts and refines rare earth elements from unconventional sources, aimed at strengthening domestic supply chains and reducing reliance on foreign materials.